Have a feature idea you'd love to see implemented? Let us know!

IDYA IDEAYA Biosciences Inc

Price (delayed)

$29.99

Market cap

$2.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.33

Enterprise value

$2.21B

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates ...

Highlights
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ
The quick ratio has increased by 31% from the previous quarter and by 18% YoY
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter
The company's gross profit has shrunk by 83% YoY and by 67% QoQ

Key stats

What are the main financial stats of IDYA
Market
Shares outstanding
86.43M
Market cap
$2.59B
Enterprise value
$2.21B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
659.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
563.41
Earnings
Revenue
$3.92M
EBIT
-$178.12M
EBITDA
-$173.91M
Free cash flow
-$153.27M
Per share
EPS
-$2.33
Free cash flow per share
-$1.78
Book value per share
$13.97
Revenue per share
$0.05
TBVPS
$14.39
Balance sheet
Total assets
$1.24B
Total liabilities
$59.46M
Debt
$18.8M
Equity
$1.18B
Working capital
$891.56M
Liquidity
Debt to equity
0.02
Current ratio
22.93
Quick ratio
22.65
Net debt/EBITDA
2.2
Margins
EBITDA margin
-4,434.1%
Gross margin
100%
Net margin
-4,541.6%
Operating margin
-5,730.6%
Efficiency
Return on assets
-18.6%
Return on equity
-19.4%
Return on invested capital
-24.9%
Return on capital employed
-14.9%
Return on sales
-4,541.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IDYA stock price

How has the IDEAYA Biosciences stock price performed over time
Intraday
-1.38%
1 week
6.54%
1 month
1.97%
1 year
2.49%
YTD
-15.71%
QTD
-5.33%

Financial performance

How have IDEAYA Biosciences's revenue and profit performed over time
Revenue
$3.92M
Gross profit
$3.92M
Operating income
-$224.75M
Net income
-$178.12M
Gross margin
100%
Net margin
-4,541.6%
IDYA's operating income has dropped by 89% year-on-year and by 17% since the previous quarter
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter
The company's gross profit has shrunk by 83% YoY and by 67% QoQ
The net income has plunged by 73% YoY and by 16% from the previous quarter

Growth

What is IDEAYA Biosciences's growth rate over time

Valuation

What is IDEAYA Biosciences stock price valuation
P/E
N/A
P/B
2.15
P/S
659.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
563.41
The EPS has declined by 17% year-on-year and by 6% since the previous quarter
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ
The stock's P/B is 31% below its last 4 quarters average of 3.1 and 10% below its 5-year quarterly average of 2.4
The stock's price to sales (P/S) is 115% more than its last 4 quarters average of 306.3
The revenue has dropped by 83% year-on-year and by 67% since the previous quarter

Efficiency

How efficient is IDEAYA Biosciences business performance
The company's return on equity rose by 20% YoY and by 5% QoQ
IDYA's ROIC is up by 20% YoY and by 2.7% from the previous quarter
The ROA has grown by 18% YoY and by 6% from the previous quarter

Dividends

What is IDYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDYA.

Financial health

How did IDEAYA Biosciences financials performed over time
IDEAYA Biosciences's total liabilities has soared by 139% YoY and by 42% from the previous quarter
IDEAYA Biosciences's total assets has surged by 133% YoY and by 27% QoQ
The company's debt is 98% lower than its equity
IDEAYA Biosciences's equity has surged by 132% YoY and by 27% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.